tiprankstipranks
Advertisement
Advertisement

FATE Stock Latest News

Fate Therapeutics announces data presentation of FT839
The FlyFate Therapeutics announces data presentation of FT839
3d ago
FATE
Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
PremiumRatings
Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
2M ago
FATE
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
PremiumThe Fly
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
2M ago
FATE
Fate Therapeutics presents updated Phase 1 data of FT819
PremiumThe Fly
Fate Therapeutics presents updated Phase 1 data of FT819
4M ago
FATE
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
PremiumCompany Announcements
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
5M ago
FATE
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
PremiumCompany AnnouncementsNavigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
5M ago
FATE
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
Premium
Ratings
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
5M ago
FATE
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
Premium
The Fly
Fate Therapeutics reports Q3 EPS (27c), consensus (28c)
5M ago
FATE
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe Fly
Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
6M ago
FATE
Is FATE a Buy, Before Earnings?
PremiumPre-Earnings
Is FATE a Buy, Before Earnings?
6M ago
FATE
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
PremiumCompany Announcements
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
6M ago
FATE
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
PremiumCompany Announcements
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
6M ago
FATE
Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
PremiumCompany AnnouncementsFate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
6M ago
FATE
Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7
Premium
The Fly
Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7
6M ago
FATE
Fate Therapeutics Reports Promising Phase 1 Trial Results
Premium
Company Announcements
Fate Therapeutics Reports Promising Phase 1 Trial Results
6M ago
8K
FATE
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
PremiumThe Fly
Fate Therapeutics upgraded to Outperform from Neutral at Wedbush
6M ago
FATE
Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
PremiumRatings
Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns
6M ago
FATE
Fate Therapeutics Appoints New CFO Kamal Adawi
PremiumCompany Announcements
Fate Therapeutics Appoints New CFO Kamal Adawi
6M ago
8K
FATE
Fate Therapeutics appoints Adawi as CFO
PremiumThe Fly
Fate Therapeutics appoints Adawi as CFO
6M ago
FATE
Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
PremiumCompany AnnouncementsFate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
8M ago
FATE
Fate Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Fate Therapeutics Reports Q2 2025 Financial Results
8M ago
FATE
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
Premium
The Fly
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
8M ago
FATE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >